Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone

Objective: To investigate risk factors for Creutzfeldt-Jakob disease (CJD) in patients in the United Kingdom treated with human pituitary growth hormone (hGH). Methods: Incidence rates of CJD, based on person-year denominators, were assessed in a cohort of 1,848 patients treated with hGH in the United Kingdom from 1959 through 1985 and followed to the end of 2000. Results: CJD developed in 38 patients. Risk of CJD was significantly increased by treatment with hGH prepared by the Wilhelmi method of extraction from human pituitaries. Risk was further raised if this treatment was administered at ages 8 to 10 years. The peak risk of CJD was estimated to occur 20 years after first exposure, and the estimated lifetime cumulative risk of CJD in Wilhelmi-treated patients was 4.5%. Conclusions: Size-exclusion chromatography, used in non-Wilhelmi preparation methods, may prevent CJD infection. Susceptibility to CJD may vary with age, and susceptibility may be present in only a few percent of the population.

[1]  M. Genuardi,et al.  Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease , 1994, Human Genetics.

[2]  Y. Agid,et al.  Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK , 2003, The Lancet.

[3]  C. V. van Duijn,et al.  Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone , 2002, Journal of neurology, neurosurgery, and psychiatry.

[4]  Manjit,et al.  Neurology , 1912, NeuroImage.

[5]  J. Ironside,et al.  Variant Creutzfeldt-Jakob disease. , 2004, Folia neuropathologica.

[6]  I. Jackson,et al.  Genetic and environmental factors modify bovine spongiform encephalopathy incubation period in mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Bishop,et al.  Variant Creutzfeldt-Jakob disease in an elderly patient , 2001, The Lancet.

[8]  L. McShane,et al.  Iatrogenic Creutzfeldt–Jakob disease at the millennium , 2000, Neurology.

[9]  A. Hofman,et al.  A Nationwide Cohort Study on Creutzfeldt-Jakob Disease among Human Growth Hormone Recipients , 2000, Neuroepidemiology.

[10]  D. De Angelis,et al.  Prevalence of detectable abnormal prion protein in persons incubating vCJD: plausible incubation periods and cautious inference. , 2000, Journal of epidemiology and biostatistics.

[11]  Y. Agid,et al.  Incubation period of Creutzfeldt–Jakob disease in human growth hormone recipients in France , 1999, Neurology.

[12]  A. Alpérovitch,et al.  Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease , 1999, The Lancet.

[13]  P. Brown,et al.  Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J W Denham,et al.  A generalized F mixture model for cure rate estimation. , 1998, Statistics in medicine.

[15]  D. Dormont,et al.  Genotype at codon 129 and susceptibility to Creutzfeldt-Jakob disease , 1998, The Lancet.

[16]  Michael Wall,et al.  Friendly Fire , 1998 .

[17]  S. Cousens,et al.  Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96 , 1997, BMJ.

[18]  R. G. Will,et al.  Predicting the CJD epidemic in humans , 1997, Nature.

[19]  Y. Agid,et al.  Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France , 1996, Neurology.

[20]  R. Lathe,et al.  Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene , 1996, Human Genetics.

[21]  Z. Laron,et al.  Safety of pituitary growth hormone extracted with acetone/acetic acid , 1994, The Lancet.

[22]  T. Foley,et al.  Clinical review 58: Creutzfeldt-Jakob disease in recipients of pituitary hormones. , 1994, The Journal of clinical endocrinology and metabolism.

[23]  P. Brown,et al.  Iatrogenic Creutzfeldt‐Jakob disease , 1994, Neurology.

[24]  I. Bjarnason,et al.  Inflammatory bowel disease of mice—and men? , 1994, The Lancet.

[25]  P. Brown,et al.  "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease , 1992, The Lancet.

[26]  C. Frith,et al.  Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. , 1992, Brain : a journal of neurology.

[27]  S. Prusiner,et al.  Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene , 1992, Nature Genetics.

[28]  M. Preece,et al.  Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. , 1991, BMJ.

[29]  D. Wysowski,et al.  Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. , 1991, JAMA.

[30]  J. Goujard,et al.  Human pituitary growth hormone (hGH) and Creutzfeldt-Jakob disease: results of an epidemiological survey in France, 1986. , 1988, International journal of epidemiology.

[31]  M. Fisman.  Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. , 1986, The New England journal of medicine.

[32]  P. Brown.  VIRUS STERILITY FOR HUMAN GROWTH HORMONE , 1985, The Lancet.

[33]  H. Fraser,et al.  PREPARATION OF GROWTH HORMONE FREE FROM CONTAMINATION WITH UNCONVENTIONAL SLOW VIRUSES , 1985, The Lancet.

[34]  M. Preece,et al.  CREUTZFELDT-JAKOB DISEASE AFTER ADMINISTRATION OF HUMAN GROWTH HORMONE , 1985, The Lancet.

[35]  M. Alpers,et al.  The Natural Incubation Period of Kuru and the Episodes of Transmission in Three Clusters of Patients , 1984 .

[36]  G. Benker,et al.  Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use. , 1979, The Journal of endocrinology.

[37]  J. Tanner,et al.  EXPERIENCE WITH HUMAN GROWTH HORMONE IN GREAT BRITAIN: THE REPORT OF THE MRC WORKING PARTY , 1979, Clinical endocrinology.

[38]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[39]  J. B. Mills,et al.  Improved method for the extraction and purification of human growth hormone. , 1969, The Journal of clinical endocrinology and metabolism.

[40]  M. Raben.  Treatment of a pituitary dwarf with human growth hormone. , 1958, The Journal of clinical endocrinology and metabolism.